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ABSTRACT 
Background: In recent years, the use of generic drugs has been increasing 
due to their effectiveness and to the increasing variety of drugs that are now 
available in generic formulations. Although several generic oral formulations of
azithromycin are available in China, information concerning the bioavailability 
of these formulations in the Chinese population is unavailable. 
Objective: The purpose of this study was to compare the bioequivalence 
and tolerability of a single oral dose of 2 commercial brands of 500-mg azithro- 
mycin granules in healthy Han Chinese volunteers. 
Methods: In a randomized, open-label, 2-period crossover study, the bio- 
equivalence and tolerability of 2 commercial formulations of azithromycin gran- 
ules (test: Dayin Ocean Biochemical Company Ltd., Shandong, China; refer- 
ence: Taiyang Drug Company Ltd., Beijing, China) were compared in healthy 
adult Han Chinese volunteers. Both the test and the reference formulations 
were administered to each subject. The 2 treatment phases were separated by 
a 3-week washout period. Liquid chromatography-tandem mass spectrometry 
was used to determine plasma drug concentrations. The formulations were 
considered bioequivalent if the natural log-transformed ratios of Cma xand AUC 
were within the predetermined quivalence range of 70% to 143% and 80% to 
125%, respectively, and if P < 0.05 for the 90% CIs. 
Results: Twenty-four male Han Chinese volunteers (mean [SD] age, 21.0 
[2.0] years [range, 18-25 years]; mean [SD] weight, 67.6 [5.6] kg [range, 56- 
81 kg]; mean [SD] height, 176.0 [5.0] cm [range, 165-188 cm]) were enrolled. 
Twenty-two subjects completed the study, with 2 withdrawing for personal 
reasons. No period or sequence ffect was observed. The 90% CIs for the 
corresponding ratios of Cma x, AUC from hour 0 to time t, and AUC from hour 
0 to any time point were 85.9 to 103.9, 83.6 to 106.0, and 84.7 to 105.9 (in the 
2 one-sided t tests; all, P < 0.05), respectively. Similar results were found in 
data without a logarithmic transformation. There were no significant differences 
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in the plasma concentration-time curves of the test and reference formulations. 
No adverse events were reported by the subjects or revealed by clinical or 
laboratory tests. 
Conclusions: Single oral doses of 2 commercial brands of azithromycin gran- 
ules (500 mg) were equivalent with regard to the rate and extent of absorption 
among these healthy Han Chinese volunteers. Both formulations were well 
tolerated. (Curt Ther Res Clin Exp. 2007;68:369-377) Copyright © 2007 Excerpta 
Medica, Inc. 
Key words: bioequivalence, pharmacokinetic parameters, azithromycin, 
Han Chinese volunteers, mass spectrometry. 
INTRODUCTION 
Azithromycin is a semisynthetic azalide, a subclass of the macrolide antibiotics, 
that is similar to erythromycin but is composed of a 15-member lactone ring. 
Compared with erythromycin, azithromycin exhibits an extensive spectrum of 
activity, improved acid stability, more favorable pharmacokinetic parameters, 
and a lower prevalence of adverse vents (AEs) and drug interactions. 1,2In clini- 
cal practice, the drug plays an important role in the treatment of skin infections 
and sexually transmitted and respiratory diseases. 1,3,4 For these reasons, azithro- 
mycin has been widely used in China since 1993. Azithromycin's share of the mac- 
rolide antibiotic market in China increased from 38% in 2000 to 63% in 2005. 5
In recent years, the use of generic drugs has increased ue to their effec- 
tiveness and the increasing variety of drugs that are now available in generic 
formulations. However, their use in clinical practice depends not only on their 
essential similarity (in formulation and composition, as determined by regula- 
tory agencies), but also on their bioequivalence with their reference counter- 
parts. Therefore, study of the comparative bioavailabilities oftest and reference 
formulations i important for appropriate assessment by the scientific ommu- 
nity. 6 When 2 formulations of the same drug present similar bioavailabilities 
to the extent hat they are considered bioequivalent by certain criteria, 6,7 it is 
assumed that pharmaceutical equivalents are those whose rate and extent of 
absorption are not statistically different when administered to patients or sub- 
jects at the same molar dose under similar experimental conditions. 8 
Azithromycin is administered orally. Several studies have reported the 
bioavailability of oral azithromycin in different populations (eg, Mexican, 9
Italian, 1° Iranian, n and Dutchl2). Although several generic oral formulations of 
azithromycin are available in China and azithromycin was ranked the 19th most 
frequently used drug in a sample of Chinese hospitals in 2006, 5 no information 
concerning the bioavailability of these formulations in the Chinese population 
is available. 
The aim of the present study was to compare the bioequivalence and tolera- 
bility of 2 commercial brands of azithromycin (500 mg) in healthy Han Chinese 
volunteers. 
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SUBJECTS AND METHODS 
Subjects 
Eligible subjects were Han Chinese volunteers aged 18 to 27 years who were 
in good health and free of acute or chronic diseases, as documented by pre- 
study medical records, vital signs (temperature, heart rate [HR], blood pressure 
[BP], respiratory rate [RR], electrocardiography [ECG]), and routine clinical 
laboratory tests (hematology, serum biochemistry, urinalysis). Subjects were 
excluded if they had a history of hepatic, renal, cardiovascular, or gastrointes- 
tinal disease or known allergy to any drugs. Subjects were instructed to abstain 
from administering any medication for _>2 weeks before the study initiation. 
The volunteers were recruited in the Clinical Pharmacology Studies Unit 
(West China Second University Hospital, Sichuan University, Chengdu, China). 
Each subject provided written informed consent for participation and was 
compensated financially. 
Study Design 
The investigations were approved by the ethics and research committee 
at Sichuan University and carried out in accordance with the Declaration of 
Helsinki 13 and the guidelines for Good Clinical Practice. 14 
A randomized, open-label, 2-period crossover design was used. After a 12-hour 
(overnight) fast, each participant randomly received a single dose of the test or 
reference formulation based on a computer-generated random number table. The 
test formulation was 500 mg of azithromycin granules (batch no. 05100, Dayin 
Ocean Biochemical Company Ltd., Shandong, China); the reference formula- 
tion was also 500 mg of azithromycin granules (batch no. 060108, Taiyang Drug 
Company Ltd., Beijing, China). Participants completed a 3-week washout period 
between the 2 treatments. Both the test and reference products were compared 
in each subject so that intersubject variables were balanced. 
Blood samples were collected in heparinized tubes (Haimen Instrument, 
Jiangsu, China) predose (hour 0) and at 0.25, 0.5, 1.0, 1.5, 2.0, 2.5, 3, 4, 12, 36, 60, 
84, 108, and 156 hour(s) postadministration. Plasma was immediately separated 
by centrifugation at4000 rpm for 10 minutes and stored at -20°C until analysis. 
Determination of Plasma Azithromycin Concentration 
A sensitive, rapid liquid chromatography-tandem mass spectrometry 
method for determining azithromycin concentration i human plasma was 
developed and validated in previous studies. 15,16 First, 0.5 mL of plasma plus 
50 1JL of internal standard (finasteride 2 1Jg/mL), 200 1JL of sodium hydroxide 
0.5 M, and 3 mL of ethyl acetate were mixed in a test tube and vortexed for 
5 minutes (vortex WH-3, Anting Scientific Instrument, Shanghai, China). The 
tube was centrifuged at 14,000 rpm for 5 minutes (Anke TGL-16C centrifuge, 
Anting Scientific Instrument). The organic phase was transferred to another 
tube and evaporated until dry at 40°C under a nitrogen stream. The dry residue 
was redissolved in 100 1JL of mobile phase. After centrifugation at 14,000 rpm 
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for 5 minutes, 20 1JL of the supernatant was injected into the chromatographic 
system. The compounds were separated in a reversed-phase Diamonsil C18 
column (150 x 4.6 mm, inner diameter, 5 1Jm; Dikma Technologies, Beijing, 
China) and eluted with a mobile phase consisting of 10 mM ammonium acetate 
(pH 3.5):methanol (20:80, v/v), which was pumped at a flow rate of 1.0 mL/min 
with a split ratio of 20:80. The column temperature was 40°C. Detection was 
carried out by multiple-reaction monitoring using the respective [M+H]+ ions, 
m/z 375.4/591.5 for azithromycin and m/z 373.4/305.4 for the internal standard. 
The analytical equipment used included a high-performance liquid chromatog- 
raphy device (model 1100, Agilent, Palo Alto, California) coupled with a mass 
detector (API 3000 triple quadruple instrument, Applied Biosystems, Foster 
City, California). Under these conditions, the method was linear over the range 
of 5 to 1500 ng/mL, accuracy was between 90% and 100%, and the relative SD of 
the method was <13%. According to the validation report, this modified method 
was considered suitable for pharmacokinetic study of azithromycin. 
Tolerability Assessment 
To assess tolerability, vital signs (temperature, HR, BP, and RR) were mea- 
sured and subjects were questioned about AEs after drug administration. 
Laboratory analyses (hematology, serum biochemistry, and urinalysis) and 
ECG were also performed prestudy and poststudy. Tolerability of the 2 formu- 
lations was the secondary assessment end point; therefore, only descriptive 
statistics were reported. 
Pharmacokinetic and Statistical Analyses 
Assuming a 13 of 0.2, it was determined that to achieve a power of 80% (analy- 
sis of variance [ANOVA]) with a 90% CI, a total of 22 subjects would be needed 
for the purposes of this study. 
All pharmacokinetic (PK) and statistical analyses were performed using 
Drug And Statistics (DAS) software, Version 2.0 (DAS, Anhui, China). Cma xand 
Tma x were obtained irectly from observed plasma concentration-time curves. 
AUC from hour 0 to time t (AUC0__,t) was calculated using the linear trapezoidal 
method, whereas AUC from hour 0 to any time point (AUC0__,~) was calculated 
as the sum of AUC0~ t and the ratio of time of the last measurable concentration 
over the elimination rate constant (Ct/Ke). K e was obtained from the slope of the 
terminal log-linear phase of the semilog plot of concentration versus time. The 
tl/2 was calculated as natural log (ln)2/K e. 
To demonstrate he bioequivalence of the formulations tested, ANOVA for 
a 2-period crossover design for logarithmically (e-base) transformed Cmax, 
AUC0~t, and AUC0~ ~ was carried out. Ratios of In Cm~x, In AUC0~t, and In 
AUC0~ ~ for both formulations were calculated, and 90% CIs were obtained. 
ANOVA was performed using the Ftest. The probability of exceeding the limits 
of acceptance (80%-125%, US Food and Drug Administration [FDA] guidelines 17) 
was obtained using 2 one-sided t tests. 18 The formulations were considered 
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bioequivalent if the In-transformed ratios of Cma xand AUC were within the pre- 
determined equivalence range of 70% to 143% and 80% to 125%, respectively, 
and if P < 0.05 for the 90% CIs. 7 
RESULTS 
Twenty-four healthy Han Chinese male volunteers (mean [SD] age, 21.0 [2.0] years 
[range, 18-25 years]; mean [SD] weight, 67.6 [5.6] kg [range, 56-81 kg]; mean 
[SD] height, 176.0 [5.0] cm [range, 165-188 cm]) were included in the study. 
Two subjects withdrew during the study for personal reasons. The results of 
22 subjects were included in the PK analysis. Mean plasma azithromycin con- 
centrations of both the test and reference formulations are presented in the 
figure. There were no significant differences in the plasma concentration-time 
curves of the test and reference formulations. 
Pharmacokinet ic  Parameters 
For the test formulation, the mean (SD) Cma x was  426.7 (133.8) ng/mL and 
the mean (SD) Tm~ Xwas 2.0 (0.7) hours; for the reference formulation, the C ..... 
was 482.7 (149.7) ng/mL and the Tma x was  2.1 (0.8) hours. Mean (SD) tl/2 values 
of the test and reference formulations were 53.9 (23.4) and 57.3 (29.0) hours, 
respectively. PK properties are shown in Table I. No significant between-group 
differences were found. No period or sequence ffects were observed for the 
PK properties in the ANOVA. 
Table II shows the 90% CIs of the ratios (test/reference) forthe In-transformed 
values of Cma x (as an index of rate of absorption), AUC0~t, and AUC0_~ (as an 
index of extent of absorption); the probability of exceeding the limits of accep- 
tance18; and the power of the test. 9,11,19 The 90% CIs for the corresponding ratios 
of Cmax, AUC0~t, and AUC0_~ were 85.9 to 103.9, 83.6 to 106.0, and 84.7 to 105.9 
(in the 2 one-sided t tests; all, P < 0.05), respectively. Similar results were found 
for data without a logarithmic transformation. 
Tolerabi l i ty 
No AEs were reported by the subjects or revealed by physical examination, 
vital sign measurements (body temperature, HR, BP, and RR), ECG, or labora- 
tory analyses (hematology, serum biochemistry, and urinalysis) after a single 
dose of either of the azithromycin formulations. 
DISCUSSION 
The test and reference formulations of azithromycin exhibited overlapping 
plasma profiles, especially in the elimination phase, which indicated that the 
2 formulations were similar in both absorption and elimination. 
To ensure a reliable estimate of the extent of absorption, a collection period 
of ~3 tl/2s is recommended by the US FDA 17 and the Chinese State FDA 7 guide- 
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Table I. Pharmacokinetic propert ies of 2 oral formulat ions of a single 500-mg dose of 
az i thromycin granules in healthy subjects (N -- 22). Values are mean (SD).* 
Property Test Reference 
C . . . .  ng/mL 426.7 (133.8) 482.7 (149.7) 
T . . . .  h 2.0 (0.7) 2.1 (0.8) 
tl/2, h 53.9 (23.4) 57.3 (29.0) 
AUC0~t, ng/mL • h 4171.9 (932.9) 4466.6 (1198.4) 
AUC0~,  ng/mL • h 4730.2 (918.2) 5069.3 (1374.4) 
MRT0~t, h 31.9 (8.6) 29.2 (7.2) 
AUC0~ t = AUC from hour 0 to time t; AUC0~ ~ = AUC from hour 0 to any time point; MRT = mean 
residence time. 
*No significant between-group differences were found. 
Table II. Comparison of 90% Cls of natural log ( In)-transformed Cmax, AUC0~t, and 
AUC0~o, the probabi l i ty of exceeding limits of acceptance, and power test. 
Probability of 
Exceeding Limits 
of Acceptance 
Ratio, % 
Parameter Reference 90% CI <80% >125% Power 
In Cma x 88.8 85.9--103.9 <0.008 <0.001 0.9801 
In AUCo~ t 94 .1  83.6-106.0 0.001 <0.001 0.9999 
In AUCo~ ~ 94.7 84.7-105.9 <0.008 <0.001 0.9935 
AUC0~ t = AUC from hour 0 to time t; AUC0~ ~ = AUC from hour 0 to any time point. 
lines. This requirement was fulfilled, and the mean extrapolated area was well 
below 20% for both formulations, indicating that the extract ion period was 
adequate to fully character ize the PK propert ies  of azithromycin. 6 
The AUC values obtained with the test and reference formulations were not 
significantly different, which reflects the similar PK character ist ics  of the 2 for- 
mulations, part icular ly during the elimination phase. The 90% CIs constructed 
around the ratio of expected geometr ic  means  for AUC after administrat ion of 
each formulation was 0.836 to 1.060. Because this was well within the bioequiv- 
alence range of 0.8 to 1.25, the 2 formulations can be considered bioequivalent 
according to the US FDA's definition of bioequivalence with respect  to the 
extent of absorpt ion.  8 In addition, no significant difference was observed in 
Cma x and Tma x values of the test and reference formulations. In this study, the 
PK values for both formulations were in accordance with findings reported in 
Mexican subjects by Pineyro-Lopez et al. 9 
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Estimated tl/2 values for both formulations were also consistent with those 
reported in Mexican subjects (~50 hours). 9However, tl/2 values of Iranian sub- 
jects 11 were shorter (~10 hours) and tl/2 values of Dutch subjects 12 were longer 
(~96 hours) compared with Han Chinese subjects, indicating that race might 
be an influential factor. In another clinical trial, 1° the tl/2 in Italian subjects was 
not reported because the duration of sampling was not sufficient o determine 
it with adequate precision. 
This study was limited by the small sample size of healthy volunteers and by 
using only a single dose of azithromycin. Larger studies in both healthy volun- 
teers and clinical patients are needed to obtain more definitive results and to 
compare the PK characteristics of different races comprehensively. 
CONCLUSIONS 
In this study, a single 500-mg dose of 2 commercial brands (test and reference 
formulations) of azithromycin were compared in these healthy Han Chinese 
subjects. The rate and extent of drug absorption of both formulations were not 
significantly different. Elimination was also similar between the 2 formulations, 
indicating they were bioequivalent according to the FDA definition. Both formu- 
lations were well tolerated. 
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